Business · Companies · 3 hrs ago
Neurosterix raises $105 million for planned schizophrenia drug study
Neurosterix has raised $105 million in a Series B funding round led by a group of life-sciences investors.
The company is a spin-out of biotech firm Addex, which did not take part in the funding round.
Addex now holds 8.5% of Neurosterix's issued capital, valued at $18.6 million.
The funding will support a planned Phase II study of NTX-253, a drug candidate being developed to treat schizophrenia.
NTX-253 is designed to act on a receptor through a mechanism called positive allosteric modulation.
The money will also support Neurosterix's wider drug pipeline for neuropsychiatric conditions.
The next stated step is the planned clinical study; no start date was given.
Neurosterix has completed a $105 million Series B financing.
A consortium of leading life-sciences investors led the funding round.
The funds will support a planned Phase II clinical study of NTX-253 for schizophrenia.
The financing will also support Neurosterix’s broader pipeline of selective allosteric modulators for neuropsychiatric disorders.
Addex, the biotech company from which Neurosterix was spun out, did not participate in the financing.
- Who
- Neurosterix, a spin-out of biotech company Addex, raised the funding.
- What
- It completed a $105 million Series B financing. The funds will support a planned Phase II study of NTX-253.
- When
- The announcement was made on Wednesday evening; the article was published on November 11, 2026.
- Where
- Not stated.
- Why
- To fund a planned clinical study of NTX-253 for schizophrenia and support Neurosterix’s broader pipeline.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Funding
- $105 million
- Financing round
- Series B
- Planned study
- Phase II clinical study of NTX-253
- Target condition
- Schizophrenia
- Addex stake
- 8.5% of Neurosterix’s issued capital after the financing